These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

309 related items for PubMed ID: 18667139

  • 1. Initiating insulin in patients with type 2 diabetes.
    Aoki TJ, White RD.
    J Fam Pract; 2007 Aug; 56(8 Suppl Hot Topics):S12-20. PubMed ID: 18667139
    [Abstract] [Full Text] [Related]

  • 2. Defining the role of incretin mimetic therapy in the management of type 2 diabetes.
    Unger J, Nadeau DA.
    J Fam Pract; 2007 Dec; 56(12 Suppl New):S4-S10. PubMed ID: 18664341
    [Abstract] [Full Text] [Related]

  • 3. Beta-cell function and mass in type 2 diabetes.
    Larsen MO.
    Dan Med Bull; 2009 Aug; 56(3):153-64. PubMed ID: 19728971
    [Abstract] [Full Text] [Related]

  • 4. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.
    Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Gravina A, Mereu R, Palumbo I, D'Angelo A, Cicero AF.
    Metabolism; 2009 Aug; 58(8):1059-66. PubMed ID: 19394976
    [Abstract] [Full Text] [Related]

  • 5. Treating postprandial hyperglycemia does not appear to delay progression of early type 2 diabetes: the Early Diabetes Intervention Program.
    Kirkman MS, Shankar RR, Shankar S, Shen C, Brizendine E, Baron A, McGill J.
    Diabetes Care; 2006 Sep; 29(9):2095-101. PubMed ID: 16936159
    [Abstract] [Full Text] [Related]

  • 6. Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression.
    Zhang H, Wei J, Xue R, Wu JD, Zhao W, Wang ZZ, Wang SK, Zhou ZX, Song DQ, Wang YM, Pan HN, Kong WJ, Jiang JD.
    Metabolism; 2010 Feb; 59(2):285-92. PubMed ID: 19800084
    [Abstract] [Full Text] [Related]

  • 7. Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone.
    Derosa G, D'Angelo A, Salvadeo SA, Ferrari I, Gravina A, Fogari E, Maffioli P, Cicero AF.
    Metabolism; 2008 Nov; 57(11):1552-7. PubMed ID: 18940393
    [Abstract] [Full Text] [Related]

  • 8. Treatment of type 2 diabetes with combined therapy: what are the pros and cons?
    Massi-Benedetti M, Orsini-Federici M.
    Diabetes Care; 2008 Feb; 31 Suppl 2():S131-5. PubMed ID: 18227473
    [Abstract] [Full Text] [Related]

  • 9. Redefining insulin therapy in type 2 diabetes mellitus.
    Rosenstock J.
    Postgrad Med; 2004 Nov; 116(5 Suppl Exploring):21-9. PubMed ID: 19667676
    [Abstract] [Full Text] [Related]

  • 10. Rationale and design of a clinical trial to evaluate metformin and colesevelam HCl as first-line therapy in type 2 diabetes and colesevelam HCl in prediabetes.
    Jones MR, Mudaliar S, Hernandez-Triana E, Unnikrishnan AG, Lai YL, Abby SL, Misir S, Jin X, Nagendran S.
    Curr Med Res Opin; 2009 Sep; 25(9):2239-49. PubMed ID: 19622007
    [Abstract] [Full Text] [Related]

  • 11. Homeostasis model assessment (HOMA) as surrogate insulinization criteria in patients with type 2 diabetes.
    Bermúdez V, Cano R, Cano C, Bermúdez F, Leal E, Acosta K, Mengual E, Arraiz N, Briceño C, Gómez J, Bustamante M, Aparicio D, Cabrera M, Valdelamar L, Rodriguez M, Manuel V, Hernández R.
    Am J Ther; 2008 Sep; 15(4):409-16. PubMed ID: 18645347
    [Abstract] [Full Text] [Related]

  • 12. [Characteristics of glycemic excursion in different subtypes of impaired glucose intolerance].
    Kang Y, Lu JM, Sun JF, Li CL, Wang XL, Zhang XQ, Lü ZH, Dou JT, Mu YM.
    Zhonghua Yi Xue Za Zhi; 2009 Mar 17; 89(10):669-72. PubMed ID: 19595059
    [Abstract] [Full Text] [Related]

  • 13. Oral combination therapy with thiazolidinediones in type 2 diabetes.
    LaSalle JR, Cross LB.
    Am J Manag Care; 2006 Nov 17; 12(14 Suppl):S369-81. PubMed ID: 17112324
    [Abstract] [Full Text] [Related]

  • 14. [Evaluating the feature of hypoglycemia detected by continuous glucose monitoring system during temporary continuous subcutaneous insulin infusion in type 2 diabetes patients].
    Li M, Zhou J, Bo YQ, Lu W, Jia WP, Xiang KS.
    Zhonghua Yi Xue Za Zhi; 2008 Jun 24; 88(24):1679-82. PubMed ID: 19024537
    [Abstract] [Full Text] [Related]

  • 15. [Postprandial blood glucose as the driving force in pathogenesis of type 2 diabetes].
    Liebl A.
    Med Klin (Munich); 2003 Oct 15; 98 Suppl 1():7-11. PubMed ID: 14694835
    [Abstract] [Full Text] [Related]

  • 16. When oral agents fail: optimizing insulin therapy in the older adult.
    Meece J.
    Consult Pharm; 2009 Jun 15; 24 Suppl B():11-7. PubMed ID: 19555131
    [Abstract] [Full Text] [Related]

  • 17. Dyslipidemia in type 2 diabetes.
    Krauss RM, Siri PW.
    Med Clin North Am; 2004 Jul 15; 88(4):897-909, x. PubMed ID: 15308384
    [Abstract] [Full Text] [Related]

  • 18. Building cultural competency for improved diabetes care: Latino Americans and diabetes.
    Cabellero AE, Tenzer P.
    J Fam Pract; 2007 Sep 15; 56(9 Suppl Building):S7-13. PubMed ID: 18667137
    [Abstract] [Full Text] [Related]

  • 19. Selecting among ADA/EASD tier 1 and tier 2 treatment options.
    McGill JB.
    J Fam Pract; 2009 Sep 15; 58(9 Suppl Treating):S26-34. PubMed ID: 19744422
    [Abstract] [Full Text] [Related]

  • 20. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities.
    Resmini E, Minuto F, Colao A, Ferone D.
    Acta Diabetol; 2009 Jun 15; 46(2):85-95. PubMed ID: 19322513
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.